• Duphat
  • infinia camp
  • Emirates Digestive Diseases
MedEdge MEA MedEdge_Logo_Dark

Public Relations, Top Health Magazine and Healthcare News GCC

  • Newsletters
  • Magazines
  • Subscribe
  • Home
  • News
  • Opinion
  • Interviews
  • Featured
  • Cover Stories
  • Events
  • Health For all
    • Ageing Gracefully
    • Family Health Matters
    • Environment Health
    • Women and Child Health
    • Men’s Health
  • Resource Hub
    • Fresh Perspectives
    • Medical Tourism
    • Medical Education
    • Personnel
    • Research
      • Healthcare Journals & Publishers
    • Healthcare Campaigns
    • Health Tools Hub
    • Dubai Health Centers Directory | Services, Locations & Timings
    • ME Explained
Reading: Adagio Medical selects Todd Usen as new CEO and Director
Share
Notification
  • Duphat
  • infinia camp
  • Emirates Digestive Diseases
MedEdge MEA
  • Magazines
  • Newsletters
  • Profiles
  • Subscribe
Search
  • Home
  • News
  • Opinion
  • Interviews
  • Featured
  • Cover Stories
  • Events
  • Health For all
    • Ageing Gracefully
    • Family Health Matters
    • Environment Health
    • Women and Child Health
    • Men’s Health
  • Resource Hub
    • Fresh Perspectives
    • Medical Tourism
    • Medical Education
    • Personnel
    • Research
    • Healthcare Campaigns
    • Health Tools Hub
    • Dubai Health Centers Directory | Services, Locations & Timings
    • ME Explained
Have an existing account? Sign In
MedEdge MEA > Resource Hub > Personnel > Adagio Medical selects Todd Usen as new CEO and Director
Personnel

Adagio Medical selects Todd Usen as new CEO and Director

ME Desk
ME Desk
Published: December 17, 2024
Share
3 Min Read
Adagio
SHARE

December 16 2024- Adagio Medical Holdings, Inc. announced that founder Olav Bergheim departed as Chief Executive Officer and Chairperson of the Board of Directors of the Company, effective December 13, 2024. Concurrently, the Company announced the appointment of Todd Usen, as Chief Executive Officer and Director of the Company and Orly Mishan, as Chairperson of the Board of Directors, effective December 13, 2024. Mr. Bergheim will serve as an advisor to the Company and will support Mr. Usen with the transition through December 13, 2025.

โ€œWe are grateful to Olav for his dedication and contributions to Adagio. Under his leadership the Company made substantial clinical and operational strides, and is NASDAQ-listed,โ€ said Orly Mishan. โ€œWe are extremely fortunate to add Todd, who has a breadth of commercial and operational experience and a proven track record leading large and complex medical device businesses, to the Adagio team. Todd has demonstrated exceptional leadership in building, restructuring, and growing public and private organizations. His efforts have been driven by a strong focus on corporate development, product innovation, logistics and go-to-market strategies.โ€

โ€œIโ€™m thrilled to join Adagio at this important junction in the Companyโ€™s history, supporting initial commercial efforts in Europe, and the FULCRUM-VT trial enrollment in the United States,โ€ said Todd Usen. โ€œWith a growing body of evidence demonstrating both the safety and effectiveness of Adagioโ€™s Ultra-Low Temperature Cryoablation technology and marked enthusiasm of users in both Europe and North America, I believe that Adagioโ€™s VT Cryoablation System with vCLAS catheter will become the future standard of care for treatment of patients with ventricular tachycardia.โ€

Also Read : AnimalhealthEurope welcomes Pieter-Jan Serreyn as new technical director

โ€œIt has been an honor to lead Adagio over the last 13 years delivering on our mission of improving the quality of life and long-term outcomes in patients with cardiac arrhythmias. I am proud of what we have accomplished together, and I am confident that Adagio is poised for continued success,โ€ said Olav Bergheim.

Share This Article
Facebook Whatsapp Whatsapp LinkedIn Copy Link
Share
Previous Article Germany Boehringer Ingelheim and VSF Germany unite to fight Rabies in Kenya
Next Article Jim Scibetta VectorY Therapeutics names Jim Scibetta as new CEO

Recent Posts

  • NIH research clears way for study of experimental treatment for opioid use disorder
  • ASCO awards Eduardo Vilar-Sanchez, M.D., Ph.D., for cancer prevention research | ASCO 2026
  • King Faisal Hospital Ranks 12th Globally in Brand Finance 2026
  • Seventy-ninth World Health Assembly honours global champions advancing primary health care
  • DRC and WHO Issue Joint Statement on Bundibugyo Ebola Outbreak
  • duphat
  • MedEdge-Infinia
Two Point Five Logo white
  • About Us
  • Contact Us
  • Medical Disclaimer
  • Privacy Policy
  • Terms and Conditions
  • Cookie Policy (EU)
  • Submit Your Story
  • MediaKit
Reading: Adagio Medical selects Todd Usen as new CEO and Director
Share

Published by Two Point Five Media FZCO

  • About Us
  • Contact Us
  • Medical Disclaimer
  • Privacy Policy
  • Terms and Conditions
  • Cookie Policy (EU)
  • Submit Your Story
  • MediaKit
Reading: Adagio Medical selects Todd Usen as new CEO and Director
Share

Follow US on Social Media

Facebook Instagram Linkedin X-twitter Youtube Whatsapp
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}

WhatsApp us

Logo of Medede mea
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?